• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CLBS

CLBS

Caladrius Biosciences, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.43

-0.09 (-16.75%)

Company Profile

CEO

David Mazzo

IPO Date

1995-11-03

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.65

Prev. Close

$0.51

Day Low

$0.38

Day High

$0.65

Market Cap

$0.00B

Volume

26.95M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

13.3%

Avg Negative

3.8%

Avg Neutral

82.8%

News Feed

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/5/2021·↓ negative

Caladrius Biosciences, Inc. (CLBS) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research·8/5/2021·↑ positive

Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time

GlobeNewsWire
·7/29/2021
·↑ positive

Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit

GlobeNewsWire·6/17/2021·↓ negative

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/7/2021·↓ negative

Caladrius Biosciences, Inc. (CLBS) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time

GlobeNewsWire·4/29/2021·↑ positive

Is the Options Market Predicting a Spike in Caladrius Biosciences (CLBS) Stock?

Zacks Investment Research·3/8/2021·↑ positive

Caladrius Biosciences, Inc. (CLBS) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research·3/4/2021·↑ positive

Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

GlobeNewsWire·3/3/2021·↑ positive